Skip to main content
SpringerLink
Log in

Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma

  • Original Article—Liver, Pancreas, and Biliary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

Injection of a suspension of miriplatin into the hepatic artery has been employed for the treatment of hepatocellular carcinoma (HCC). The efficacy and safety of transcatheter arterial chemoembolization (TACE) using miriplatin were evaluated.

Methods

A total of 236 patients with unresectable HCC received miriplatin administration through the hepatic artery, followed by embolization with porous gelatin particles. The efficacy of this treatment modality was evaluated by contrast-enhanced computed tomography performed 1 month later and its safety based on the Common Terminology Criteria for Adverse Events (CTCAE).

Results

Miriplatin was used at a median dose of 66 mg. The therapeutic efficacy was evaluated in 130 patients, and the overall and complete response rates were 70.0 and 37.7%, respectively. The efficacies differed depending on the staging and Japan integrated staging (JIS) scores of the HCCs, with the overall and complete response rates being 87.7 and 66.7% for stage I and stage II HCC, and 56.2 and 15.1% for stage III and stage IV HCC, respectively; the corresponding rates were 93.2 and 70.5%, respectively, for HCCs with score 0 and score 1, and 58.1 and 20.9%, respectively, for those with scores 2–4. The stage of HCC was a significant independent factor associated with curative effects of TACE using miriplatin. Grade 3 elevation of serum transaminase levels was found in 23.4% of the patients; however, the values returned to the baseline levels.

Conclusions

Miriplatin is a useful and safe agent for TACE in patients with HCC stage I or II and/or JIS score 0 or 1 only when radiofrequency ablation and liver resection cannot be performed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44(Suppl):102–7.

    Article  PubMed  Google Scholar 

  2. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, et al. Management of hepatocellular carcinoma: report of consensus meeting in the 45th annual meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:667–85.

    Article  PubMed  Google Scholar 

  3. Ikai I, Arii S, Ichida T, Okita K, Omata M, Kojiro M, et al. Report of the 16th follow-up survey of primary liver cancer. Hepatol Res. 2005;32:163–72.

    Article  PubMed  Google Scholar 

  4. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–7.

    Article  PubMed  Google Scholar 

  5. Rossi S, Buscarini E, Garbagnati F, Garbagnati F, Stasi MD, Quaretti P, et al. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. Am J Roentgenol. 1998;170:1015–22.

    CAS  Google Scholar 

  6. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000;32:1224–9.

    Article  PubMed  CAS  Google Scholar 

  7. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.

    Article  PubMed  CAS  Google Scholar 

  8. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.

    Article  PubMed  Google Scholar 

  9. Sumie S, Yamashita F, Ando E, Tanaka M, Yano Y, Fukumori K, et al. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. Am J Radiology. 2003;181:1327–34.

    Google Scholar 

  10. Okusaka T, Kasugai H, Ishii H, SM-11355 Japan Study Group. A randomized phase II trial of intraarterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in comparison with zinostatin stimalamer in patients with hepatocellular carcinoma. J Clin Oncol. 2009;27:222s.

    Article  Google Scholar 

  11. Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology. 1987;163:345–51.

    PubMed  CAS  Google Scholar 

  12. Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, et al. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. Am J Radiol. 2010;194:830–7.

    Google Scholar 

  13. The Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. Tokyo: Kanehara; 2003.

  14. Kudo M, Cung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan integrated staging score (JIS score). J Gastroenterol. 2003;38:207–15.

    Article  PubMed  Google Scholar 

  15. National Cancer Institute. Common terminology criteria for adverse events (CTCAE), version 4.0. 2011. http://evs.nci.nih.gov/ftp1/CTCAE/. Accessed 9 May 2011.

  16. Nakakuma K, Tashiro S, Hiraoka T, Ogata K, Ootsuka K. Hepatocellular carcinoma and metastatic cancer detected by iodized oil. Radiology. 1985;154:15–7.

    PubMed  CAS  Google Scholar 

  17. Taguchi T, Saito T, Ota J, Nakao I, Ohashi K, Nakamura H, et al. Phase II study of YM881 (zinostatin stimalamer) suspension injected into the hepatic artery. Jpn J Cancer Chemother. 1991;18:1665–75.

    CAS  Google Scholar 

  18. Maeda H, Uchida NA, Sasaki T. Liposoluble platinum(II) complexes with antitumor activity. Jpn J Cancer Res. 1986;77:523–5.

    PubMed  CAS  Google Scholar 

  19. Kishimoto S, Noguchi T, Yamaoka T, Fukushima S, Takeuchi Y. In vitro release of SM-11355, cis[((1R,2R)-1,2-cyclohexanediamine-N,N’)bis(myristato)] platinum (II) suspended in lipiodol. Biol Pharm Bull. 2000;23:637–40.

    Article  PubMed  CAS  Google Scholar 

  20. Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N, et al. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by including platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 2009;64:473–83.

    Article  PubMed  CAS  Google Scholar 

  21. Ikeda M, Maeda S, Shibata J, Muta R, Ashihara H, Tanaka M, et al. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology. 2004;66:24–31.

    Article  PubMed  CAS  Google Scholar 

  22. Ono Y, Yoshimaru T, Ashikaga R, Inoue M, Shindou H, Fuji K, et al. Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol. 2000;23:564–8.

    Article  PubMed  CAS  Google Scholar 

  23. Yodono H, Matsuo K, Shinohara A. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma. Anti-Cancer Drugs. 2011;22:277–82.

    Article  PubMed  CAS  Google Scholar 

  24. Kawamura Y, Ikeda K, Hirakawa M, Hosaka T, Kobayashi M, Saitoh S, et al. Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin. Hepatol Res. 2009;39:346–54.

    Article  PubMed  CAS  Google Scholar 

  25. Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res. 2008;38:474–83.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported in part by Grants-in-Aid from the Ministry of Health, Labor, and Welfare of Japan to Research on Hepatitis.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, 38 Morohongo, Moroyama-cho, Iruma-gun, Saitama, 350-0495, Japan

    Yukinori Imai, Taku Chikayama, Manabu Nakazawa, Kazuhiro Watanabe, Satsuki Ando, Yoshie Mizuno, Kiyoko Yoshino, Kayoko Sugawara, Kazuhiro Hamaoka, Kenji Fujimori, Mie Inao, Nobuaki Nakayama, Masashi Oka, Sumiko Nagoshi & Satoshi Mochida

Authors
  1. Yukinori Imai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taku Chikayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manabu Nakazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazuhiro Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Satsuki Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshie Mizuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kiyoko Yoshino
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kayoko Sugawara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kazuhiro Hamaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kenji Fujimori
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mie Inao
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Nobuaki Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Masashi Oka
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Sumiko Nagoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Satoshi Mochida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yukinori Imai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Imai, Y., Chikayama, T., Nakazawa, M. et al. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Gastroenterol 47, 179–186 (2012). https://doi.org/10.1007/s00535-011-0475-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-011-0475-x

Keywords

Search

Navigation